IMPACT – MEDIUM

As of Aug. 6, Chilean citizens and foreign residents may ask the Chilean government to verify their COVID-19 vaccines that were administered abroad in order to obtain a Mobility Pass.

Key Points:

  • The vaccine verifications must be submitted through mevacuno.gob.cl. Individuals will need to consider the following when applying for validation:
    • Those with a digital vaccination document that has an advanced electronic signature or QR code do not need to submit any additional information to receive the Mobility Pass.
    • Individuals with a physical vaccination document must provide a passport or proof that the individual was in the country that is listed on the vaccination document, a positive antibodies test against COVID-19 performed by Chilean authorities at least 14 days after the vaccine was received, and a translation of the vaccination document if it is not in English or Spanish.
  • The information uploaded to mevacuno.gob.cl will be validated on a case-by-case basis; the entire validation process will take up to two weeks. Individuals will receive one of the following answers:
    • Incomplete. The application is rejected for being incomplete or inconsistent. Applicants may resubmit their request with additional information.
    • Valid. The vaccination administered abroad is accepted and the individual receives the Mobility Pass.
    • Temporarily valid. If an individual requests validation while abroad, but the vaccination document is not electronically verifiable, the individual may temporarily receive the Mobility Pass only to enter the country. To complete the validation process, the individual must provide additional information upon arrival, such as an antibody test.

Additional Information: All vaccines approved by the Chilean Institute of Public Health (ISP), the World Health Organization (WHO), the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA) may be validated in Chile.

BAL Analysis: The response to the COVID-19 pandemic continues to develop, and BAL will provide additional updates as information becomes available.

This alert has been provided by the BAL Global Practice group. For additional information, please contact berryapplemanleiden@bal.com.

Copyright © 2021 Berry Appleman & Leiden LLP. All rights reserved. Reprinting or digital redistribution to the public is permitted only with the express written permission of Berry Appleman & Leiden LLP. For inquiries, please contact copyright@bal.com.